Translational study demonstrates that NPR3 promotes metastasis and drug resistance in colorectal cancer, highlighting its potential as a prognostic biomarker and therapeutic target.
BACKGROUND: Lymph node metastasis is a critical prognostic factor in colorectal cancer (CRC). Identifying key genes associated with metastasis can improve risk stratification and treatment strategies. This study aimed to identify a gene signature related to lymph node metastasis and investigate the role of NPR3. METHODS: We analyzed the GSE878211 dataset to identify differentially expressed genes in CRC tissues with and without lymph node metastasis. A lymph node metastasis-related gene signature (LNMRGS) was constructed using Least Absolute Shrinkage and Selection Operator (LASSO) regression. The correlation between LNMRGS and clinical indicators, immune microenvironment, and signaling pathways was analyzed. The role of NPR3 was further investigated through in vitro and in vivo experiments. RESULTS: We identified 110 upregulated and 58 downregulated genes in CRC tissues with lymph node metastasis. The LNMRGS, consisting of Integrin Subunit Beta 3 (ITGB3), IQ Motif Containing with AAA Domain 1 (IQCA1), Angiopoietin-Like 4 (ANGPTL4), and Natriuretic Peptide Receptor 3 (NPR3), predicted overall survival in multiple datasets. High LNMRGS was associated with female sex, tumor recurrence, lymph node metastasis, distant metastasis, and KRAS mutations. NPR3 knockdown inhibited proliferation, migration, and invasion of CRC cells in vitro and in vivo, and reduced chemoresistance to 5-fluorouracil (5-FU) and oxaliplatin. CONCLUSION: The LNMRGS is a robust prognostic signature for CRC. NPR3 plays a key role in metastatic progression and chemoresistance, suggesting it as a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: